NCT01857947

Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER

Usefulness of Pro-adrenomedullin (MR proADM)as a Predictor of Outcome in Acute Exacerbations of COPD Visiting the Emergency Room

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 370 (actual)
• Sponsor: ThermoFisher Scientific Brahms Biomarkers France · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition to clinical evaluation is effective to predict outcome of acute exacerbations of COPD patients visiting the emergency room(ER).

Detailed description

Acute exacerbation of COPD (AECOPD)are usual and frequent cause of admission in emergency room (ER). No validated clinical or biological predictor of evolution are available. The main objective is to determine the prognosis value of Mr proADM in addition to the clinical risk stratification for AE COPD patients in ER. Patients presenting with a AECOPD diagnosis in ER will have a blood sample collected and freezed at their admission. Mr proADM will be assessed at the end of the study. Clinicians in charge of patients will not have the result during the management of their patients. This study implies no change in the patients' management. Data related to the patients'demographic,current exacerbation and basic COPD characteristics will be collected.

Conditions

• Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation

Interventions

Type	Name	Description
OTHER	AECOPD Mr proADM

Timeline

• Start date: 2013-03-01
• Primary completion: 2014-10-01
• Completion: 2014-12-01
• First posted: 2013-05-20
• Last updated: 2014-12-03

Locations

2 sites across 1 country: France